Naval G. Daver, MD

Naval Daver, MD, discusses the use of antibody-drug conjugates (ADC) in the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Naval G. Daver, MD, discusses the advancing treatment landscape in both acute myeloid leukemia and acute lymphoblastic leukemia.

Naval G. Daver, MD, discusses the utility of maintenance chemotherapy in acute myeloid leukemia.

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Naval G. Daver, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses safety differences between the TKIs ponatinib, dasatinib (Sprycel) and nilotinib (Tasigna) in the treatment of patients with chronic myeloid leukemia.

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.